Stock Ratings / Health Care / WOK / earnings

NVNO (50) SNOA (44) AMIX (37) INBS (38) ⌘ Pro Terminal →

WORK Medical Technology Group LTD (Class A) (WOK) Next Earnings Date & Expected ±12.5% Move

Q: When is WOK's next earnings date?

Based on SEC filing cadence, WORK Medical Technology Group LTD (Class A) (WOK)'s next quarterly reporting window is estimated around Dec 29, 2026.

Q: How much is WOK stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for WOK, spanning a range between $1 and $1.24.

$1.10 -4.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

WORK Medical Technology Group LTD (Class A) (WOK) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $4.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.09 (-0.97%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WOK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY WOK SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($4.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$1.53-28.8% Next Q

Q2 (-2Q)

Grade C$1.09+1.8% Next Q

Q3 (-1Q)

Grade C$1.11-0.9% Next Q

Current

Grade D+$1.10-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WOK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WOK currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.71) and Max Pain ($1.16) forces dealer call-delta covering toward $87,780.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WOK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “WOK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 29, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.14 Expected Swing

MODEL EARNINGS SETUP GAUGE

WOK Quantitative Pre-Earnings Setup: 54/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (54/100)Model Risk Weight (46/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-09-30	$0	-$1.1M	$4.9M	52%
FY 2024	2024-09-30	$0	-$3.5M	-$11.5M	52%
FY 2023	2023-09-30	$0	$112.0K	$2.2M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WOK)

✓Walkthrough of WOK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WOK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.09%▲ RESISTANCE BREAKOUT

2026-10-30O $1.07H $1.10L $1.00C $1.10VOL 60.7K

RES: $0.91SUP: $0.88SMA50: $1.71SMA200: $63.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WOK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WOK Butterfly Map → + Track WOK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WOK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WOK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WOK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WOK)

Health Care Rank #298 of 1016 ⚔️ NVNO vs WOK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WOK vs. NVNO, SNOA, AMIX, INBS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, WORK Medical Technology Group LTD (Class A) (WOK) ranks #298 by composite RQD confidence (54/100, grade D+) and #950 by equity capitalization ($4.9M). Within this direct 5-issuer industry benchmark cohort, WOK leads on earnings valuation at N/A trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WOK ACTIVE WORK Medical Technology Group LTD (Class A)	D+	54/100	—	—	—	-4.35%	$4.9M	Benchmark Subject
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-wok →
SNOA Sonoma Pharmaceuticals Inc.	D	44/100	—	38.0%	-35.0%	+5.26%	$5.7M	/snoa-vs-wok →
AMIX Autonomix Medical Inc.	D-	37/100	—	—	-35.0%	-5.12%	$4.0M	/amix-vs-wok →
INBS Intelligent Bio Solutions Inc.	D-	38/100	—	40.8%	-35.0%	+9.58%	$6.1M	/inbs-vs-wok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001929783

In its most recent audited fiscal period (FY2025, filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.1M, operating cash flow of $6.2M, and free cash flow of $4.9M (+142.9% YoY). On the balance sheet, WOK closed FY2025 with $33.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	-$1.1M	$6.2M	$4.9M	$33.2M	—
FY2024 (FY)	2024-09-30	$0	-$3.5M	-$2.2M	-$11.5M	—	—
FY2023 (FY)	2023-09-30	$0	$112.0K	$2.2M	$2.2M	—	—

3. WOK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.10 (-4.35% 1D, market cap $4.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WOK ranks #298 in composite RQD confidence.

How does WOK compare to NVNO and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $4.9M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, WOK leads on earnings multiple (N/A) while NVNO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WOK?

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $0 in revenue, -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WOK trading relative to its 50-day, 200-day, and 52-week technical levels?

WOK last traded at $1.10 (-4.35% on volume of 12,674 shares), positioning the stock -35.67% below its 50-day simple moving average ($1.71) and -98.26% below its 200-day simple moving average ($63.31). Across its 52-week range of $1.00 to $83,600.00, WOK sits at the 0.0% percentile with a 14-day RSI of 27.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.24).

WOK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is WOK's next earnings date?

Based on SEC filing cadence, WORK Medical Technology Group LTD (Class A) (WOK)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is WOK stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for WOK, spanning a range between $1 and $1.24.

Direct Sub-Reports: WOK RQD Cockpit WOK 12M Forecast WOK Earnings & Move WOK Dividends & DRIP WOK Insiders & 13F WOK Whale Options WOK Profit Sankey WOK News & Why